Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies

Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide, being characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Among several putative factors that may contribute to PD pathogenesis, inflammatory mechanisms may play a pivotal role. The involvement of microglial activation as well as of brain and peripheral immune mediators in PD pathophysiology has been reported by clinical and experimental studies. These inflammatory biomarkers evaluated by imaging techniques and/or by biological sample analysis have become valuable tools for PD diagnosis and prognosis. Regardless of the significant increase in the number of people suffering from PD, there are still no established disease-modifying or neuroprotective therapies for it. There is growing evidence of protective effect of anti-inflammatory drugs on PD development. Herein, we reviewed the current literature regarding the central nervous system and peripheral immune biomarkers in PD and advances in diagnostic and prognostic tools as well as the neuroprotective effects of anti-inflammatory therapies.

• Publication year

  2015

• Venue

  BioMed Research International

• Publication date

  2015-07-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1155/2015/628192PMID 26295044PMCID 4532803
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Parkinson's disease].

  2022cited by this paper
• Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease

  2014cited by this paper
• The international incidence and prevalence of neurologic conditions

  2014cited by this paper
• Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease

  2014cited by this paper
• Pharmacological treatment of Parkinson disease: a review.

  2014cited by this paper
• The prevalence of Parkinson's disease: A systematic review and meta‐analysis

  2014cited by this paper
• Cognitive Status Correlates with CXCL10/IP-10 Levels in Parkinson's Disease

  2014influential reference
• Abrogation of α-synuclein–mediated dopaminergic neurodegeneration in LRRK2-deficient rats

  2014cited by this paper
• Complex Deregulation and Expression of Cytokines and Mediators of the Immune Response in Parkinson's Disease Brain is Region Dependent

  2014cited by this paper
• Cerebrospinal fluid inflammatory markers in Parkinson's disease--associations with depression, fatigue, and cognitive impairment.

  2013cited by this paper
• Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies

  2013cited by this paper
• Microglia, Amyloid, and Glucose Metabolism in Parkinson’s Disease with and without Dementia

  2013cited by this paper
• Fine-Mapping, Gene Expression and Splicing Analysis of the Disease Associated LRRK2 Locus

  2013cited by this paper
• Animal models of neurodegenerative diseases.

  2013cited by this paper
• International Classification of Diseases (ICD-11) and neurologic disorders

  2013cited by this paper
• Dopaminergic therapies modulate the T‐CELL proteome of patients with Parkinson's disease

  2012cited by this paper
• Toward a redefinition of Parkinson's disease

  2012cited by this paper
• Effects of peripheral lymphocyte subpopulations and the clinical correlation with Parkinson's disease

  2012cited by this paper
• CD4+ Regulatory and Effector/Memory T Cell Subsets Profile Motor Dysfunction in Parkinson’s Disease

  2012cited by this paper
• Reduced T helper and B lymphocytes in Parkinson's disease.

  2012cited by this paper
• Non-Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Inflammatory Cytokines in Serum

  2012influential reference
• LRRK2 Inhibition Attenuates Microglial Inflammatory Responses

  2012cited by this paper
• Inflammatory cytokines and NT-proCNP in Parkinson's disease patients.

  2012influential reference
• Vaccination for Parkinson's disease.

  2012cited by this paper
• Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts

  2012cited by this paper
• Genomic determinants of motor and cognitive outcomes in Parkinson's disease.

  2012cited by this paper
• Association of Parkinson's disease with infections and occupational exposure to possible vectors

  2012cited by this paper
• Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease.

  2012cited by this paper
• Serum Levels of Chemokines in Parkinson’s Disease

  2011influential reference
• α-Synuclein Reactive Antibodies as Diagnostic Biomarkers in Blood Sera of Parkinson's Disease Patients

  2011cited by this paper
• NSAID use and risk of Parkinson disease: a population‐based case‐control study

  2011cited by this paper
• Use of ibuprofen and risk of Parkinson disease

  2011cited by this paper
• Genetic marker linking inflammation with sporadic Parkinson's disease.

  2011cited by this paper
• Non-Steroidal Anti-Inflammatory Drug Use and the Risk of Parkinson’s Disease

  2011cited by this paper
• Regulation of LRRK2 Expression Points to a Functional Role in Human Monocyte Maturation

  2011cited by this paper
• BCG Vaccine-Induced Neuroprotection in a Mouse Model of Parkinson's Disease

  2011cited by this paper
• Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease

  2011cited by this paper
• Use of non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease: nested case-control study

  2011cited by this paper
• Genome-wide association study confirms extant PD risk loci among the Dutch

  2011cited by this paper
• Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

  2011cited by this paper
• Parkinson's disease is associated with increased serum levels of macrophage migration inhibitory factor.

  2011cited by this paper
• Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance.

  2010influential reference
• Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease

  2010cited by this paper
• Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease

  2010cited by this paper
• [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?

  2010cited by this paper
• Anti-inflammatory drugs and risk of Parkinson disease

  2010cited by this paper
• Parkinsonism in patients with chronic hepatitis C treated with interferon-alpha2b: a report of two cases.

  2010cited by this paper
• Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation.

  2010cited by this paper
• Apoptosis of peripheral blood lymphocytes in Parkinson patients.

  2010cited by this paper
• NSAID Use and the Risk of Parkinson’s Disease

  2009cited by this paper
• Radiolabelled molecules for imaging the translocator protein (18 kDa) using positron emission tomography.

  2009cited by this paper
• Serum inflammatory biomarkers in Parkinson's disease.

  2009influential reference
• Peripheral cytokines profile in Parkinson's disease.

  2009cited by this paper
• Increased serum levels of soluble tumor necrosis factor-alpha receptor-1 in patients with Parkinson's disease.

  2009cited by this paper
• CXCR4 and CXCL12 Expression is Increased in the Nigro-Striatal System of Parkinson’s Disease

  2009cited by this paper
• Circulating interleukin‐10 and interleukin‐12 in Parkinson’s disease

  2009cited by this paper
• Interleukin-6 Serum Levels in Patients with Parkinson’s Disease

  2009influential reference
• Increased oxidative stress in lymphocytes from untreated Parkinson's disease patients.

  2009cited by this paper
• Neuroinflammation in the living brain of Parkinson's disease.

  2009cited by this paper
• Natural killer cells of Parkinson's disease patients are set up for activation: a possible role for innate immunity in the pathogenesis of this disease.

  2008influential reference
• Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism.

  2008cited by this paper
• Nitrated alpha‐synuclein‐activated microglial profiling for Parkinson’s disease

  2008cited by this paper
• Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study.

  2008cited by this paper
• Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk

  2008cited by this paper
• Rheumatoid arthritis accompanied by Parkinson disease.

  2008cited by this paper
• Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression.

  2008cited by this paper
• Inflammatory cytokine gene polymorphisms and increased risk of Parkinson disease.

  2007cited by this paper
• [Immune factors or depression? Fatigue correlates in Parkinson's disease].

  2007influential reference
• Peripheral inflammatory biomarkers and risk of Parkinson's disease.

  2007cited by this paper
• Rheumatoid-like hand deformities in Parkinson disease.

  2007cited by this paper
• Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease

  2007cited by this paper
• Nonsteroidal Anti-Inflammatory Drugs and the Risk of Parkinson Disease

  2007cited by this paper
• ¿Factores inmunes o depresión? La fatiga relacionada con la enfermedad de Parkinson

  2007cited by this paper
• Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease.

  2007cited by this paper
• In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease.

  2006cited by this paper
• Axonal Transport of Human Immunodeficiency Virus Type 1 Envelope Protein Glycoprotein 120 Is Found in Association with Neuronal Apoptosis

  2006cited by this paper
• Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra.

  2006cited by this paper
• Nonsteroidal anti‐inflammatory drugs and risk of Parkinson's disease

  2006cited by this paper
• Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease

  2006cited by this paper
• Interaction of polymorphisms in the genes encoding interleukin‐6 and estrogen receptor beta on the susceptibility to Parkinson's disease

  2005cited by this paper
• Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

  2005cited by this paper
• Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease

  2005cited by this paper
• Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease

  2005cited by this paper
• Alterations of T-lymphocyte populations in Parkinson disease.

  2005cited by this paper
• Microglial activation and dopamine terminal loss in early Parkinson's disease

  2005cited by this paper
• Inflammation and the Degenerative Diseases of Aging

  2004cited by this paper
• Parkinson's disease

  2004cited by this paper
• Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease

  2004cited by this paper
• Acute dystonia during pegylated interferon alpha therapy in a case with chronic hepatitis B infection.

  2004cited by this paper
• Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains

  2003cited by this paper
• Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease.

  2003cited by this paper
• Seeing through soot.

  2002cited by this paper
• Association of interleukin-1 beta polymorphisms with idiopathic Parkinson's disease.

  2002cited by this paper
• An essay on the shaking palsy. 1817.

  2002cited by this paper
• Juvenile parkinsonism as a manifestation of systemic lupus erythematosus: Case report and review of the literature

  2002cited by this paper
• Association of interleukin-1β polymorphisms with idiopathic Parkinson's disease

  2002cited by this paper
• Neuropsychiatric Effects and Type of IFN-α in Chronic Hepatitis C

  2001cited by this paper
• Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism.

  2001cited by this paper
• Amantadine in Parkinson's disease: lymphocyte subsets and IL-2 secreting T cell precursor frequencies.

  2001cited by this paper
• Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C.

  2001cited by this paper

• FGF-FGFR Signaling in Parkinson's Disease: Mechanistic Links to Ferroptosis and Neuroprotection.

  2026cites this paper
• Modulation of O-GlcNAc cycling influences α-synuclein amplification, degradation, and associated neuroinflammatory pathology

  2025cites this paper
• Microbiome Gut-Brain-Axis: Impact on Brain Development and Mental Health

  2025cites this paper
• Supplementation of the Probiotic LLH135 Reduces Oxidative Stress in a Model of Hemiparkinsonism

  2025cites this paper
• Spermidine Inhibits M1 Microglia Polarization in a Mouse Model of Parkinson's Disease and BV2 Cells via NF‐κB/STAT‐1 Pathway

  2025cites this paper
• Therapeutic potential and limitation of condensed and hydrolyzed tannins in Parkinson's disease.

  2025cites this paper
• Golexanolone affords sustained microglia and astrocytes activation improvement in a rat model of Parkinson’s disease

  2025cites this paper
• Anti-Parkinson's activity of Phragmites communis Trin. rhizomes and their liposomal formulation: Insights from chemical and molecular docking analyses.

  2025cites this paper
• In-silico identification of novel Cis-aconitate decarboxylase inhibitors as potential anti-inflammatory agents using molecular docking and dynamics

  2025cites this paper
• Anti-inflammatory effects of Iturin A on the 6-OHDA-induced SH-SY5Y cell model of Parkinson’s disease

  2025cites this paper
• Microecologics and Exercise: Targeting the Microbiota–Gut–Brain Axis for Central Nervous System Disease Intervention

  2025cites this paper
• Peptide HLDF-6 Exhibits Neuroprotective Activity in Neurodegenerative Diseases

  2025cites this paper
• Dietary supplementation with 6% blueberries (Vaccinium corymbosum L.) attenuates neurodegeneration and motor deficits in a Parkinson's Disease model.

  2025cites this paper
• An Update on the Potential of Tangeretin in the Management of Neuroinflammation-Mediated Neurodegenerative Disorders

  2024cites this paper
• Neuroinflammation-mediated white matter injury in Parkinson's disease and potential therapeutic strategies targeting NLRP3 inflammasome.

  2024cites this paper
• Association between neutrophil-to-lymphocyte ratio and motor subtypes in idiopathic Parkinson’s disease: a prospective observational study

  2024cites this paper
• Infections in the Etiology of Parkinson’s Disease and Synucleinopathies: A Renewed Perspective, Mechanistic Insights, and Therapeutic Implications

  2024cites this paper
• Unveiling Lobophytum sp. the neuroprotective potential of Parkinson's disease through multifaceted mechanisms, supported by metabolomic analysis and network pharmacology

  2024cites this paper
• Brain incoming call from glia during neuroinflammation: Roles of extracellular vesicles.

  2024cites this paper
• Effect of chlorpyrifos on cypermethrin-induced dopaminergic neurotoxicity in rats

  2024cites this paper
• The role of ACE2 in RAS axis on microglia activation in Parkinson's disease.

  2024cites this paper
• Factors derived from human exfoliated deciduous teeth stem cells reverse neurological deficits in a zebrafish model of Parkinson's disease

  2024cites this paper
• Nigrostriatal inflammation is associated with nonmotor symptoms in an experimental model of prodromal Parkinson's disease.

  2024cites this paper
• Glibenclamide-Loaded Engineered Nanovectors (GNVs) Modulate Autophagy and NLRP3-Inflammasome Activation

  2023cites this paper
• Soluble interleukin-1 receptor type 2 plasma levels in Parkinson’s disease: relationship with cardiac autonomic profile before and after peripheral mechanical somatosensory stimulation

  2023cites this paper
• Modulation of Autophagy and Nitric Oxide Signaling via Glycyrrhizic Acid and 7-Nitroindazole in MPTP-induced Parkinson’s Disease Model

  2023cites this paper
• Marine-Derived Components: Can They Be a Potential Therapeutic Approach to Parkinson’s Disease?

  2023cites this paper
• RT-DOb, a switch gene for the gene pair {Csf1r, Milr1}, can influence the onset of Alzheimer’s disease by regulating communication between mast cell and microglia

  2023cites this paper
• Advanced human iPSC-based preclinical model for Parkinson's disease with optogenetic alpha-synuclein aggregation.

  2023cites this paper
• Microbiota and nutrition as risk and resiliency factors following prenatal alcohol exposure

  2023cites this paper
• The Influence of Topinambur and Inulin Preventive Supplementation on Microbiota, Anxious Behavior, Cognitive Functions and Neurogenesis in Mice Exposed to the Chronic Unpredictable Mild Stress

  2023cites this paper
• Neuroprotective role of chloroquine via modulation of autophagy and neuroinflammation in MPTP-induced Parkinson’s disease

  2023cites this paper
• Inhibition of carnitine palmitoyl-transferase 1 is a potential target in a mouse model of Parkinson’s disease

  2023cites this paper
• TREM-1 mediates interaction between substantia nigra microglia and peripheral neutrophils

  2023cites this paper
• The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease.

  2022cites this paper
• Principal Component Analysis versus Subject’s Residual Profile Analysis for Neuroinflammation Investigation in Parkinson Patients: A PET Brain Imaging Study

  2022cites this paper
• Kurarinone alleviated Parkinson's disease via stabilization of epoxyeicosatrienoic acids in animal model

  2022influential citation
• Natural Products as Novel Neuroprotective Agents; Computational Predictions of the Molecular Targets, ADME Properties, and Safety Profile

  2022cites this paper
• Computational strategies to identify new drug candidates against neuroinflammation.

  2022cites this paper
• Role and therapeutic implications of protein glycosylation in neuroinflammation.

  2022cites this paper
• Factors Associated with Apathy in Alzheimer’s Disease: A Cross-Sectional Analysis of the Texas Alzheimer’s Research and Care Consortium (TARCC) Study

  2022cites this paper
• In Utero Exposure to Environmental Tobacco Smoke Increases Neuroinflammation in Offspring

  2022cites this paper
• Aminochrome Induces Neuroinflammation and Dopaminergic Neuronal Loss: A New Preclinical Model to Find Anti-inflammatory and Neuroprotective Drugs for Parkinson’s Disease

  2022cites this paper
• The Involvement of Kynurenine Pathway in Neurodegenerative Diseases

  2022cites this paper
• Biofluid biomarkers of amyotrophic lateral sclerosis

  2022cites this paper
• Impact of long-term air pollution exposure on incidence of neurodegenerative diseases: A protocol for a systematic review and exposure-response meta-analysis.

  2022cites this paper
• Neuroprotective and anti-inflammatory effects of pioglitazone on Parkinson's disease: A comprehensive narrative review of clinical and experimental findings.

  2022cites this paper
• Isoliquiritigenin attenuates neuroinflammation in mice model of Parkinson’s disease by promoting Nrf2/NQO-1 pathway

  2022cites this paper
• Synthetic PPAR Agonist DTMB Alleviates Alzheimer’s Disease Pathology by Inhibition of Chronic Microglial Inflammation in 5xFAD Mice

  2022cites this paper
• Peripheral Neuroprotective and Immunomodulatory Effects of 5α-Reductase Inhibitors in Parkinson’s Disease Models

  2022cites this paper
• Diagnosis and Drug Prediction of Parkinson’s Disease Based on Immune-Related Genes

  2022cites this paper
• Using Extracellular Vesicles Released by GDNF-Transfected Macrophages for Therapy of Parkinson Disease

  2022cites this paper
• Effects of Pramipexole Combined with Nerve Growth Factor on Cognitive Impairment and Urinary AD7c-NTP Expression in Patients with Parkinson's Disease

  2022cites this paper
• Association between levels of high-sensitivity C-reactive protein in plasma and freezing of gait in Parkinson's disease

  2022cites this paper
• Parkinson’s Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway

  2021cites this paper
• Flavonoids from edible fruits as therapeutic agents in neuroinflammation – a comprehensive review and update

  2021cites this paper
• CXCR4 inhibition with AMD3100 attenuates amphetamine induced locomotor activity in adolescent Long Evans male rats

  2021cites this paper
• Programmed Death-1 Deficiency Aggravates Motor Dysfunction in MPTP Model of Parkinson's Disease by Inducing Microglial Activation and Neuroinflammation in Mice

  2021cites this paper
• Effects of Boswellia serrata resin on central nervous system: a mini review

  2021cites this paper
• Pathogenic Factors and Treatment of Parkinson’s Disease

  2021cites this paper
• Impedimetric Immunosensing for Neuroinflammatory Biomarker Profiling

  2021cites this paper
• Asparagine endopeptidase deletion ameliorates cognitive impairments by inhibiting proinflammatory microglial activation in MPTP mouse model of Parkinson disease.

  2021cites this paper
• Peripheral blood lymphocyte phenotypes in Alzheimer and Parkinson's diseases.

  2021cites this paper
• The potential neuroprotective effect of diosmin in rotenone-induced model of Parkinson's disease in rats.

  2021cites this paper
• A Novel Long-Noncoding RNA LncZFAS1 Prevents MPP+-Induced Neuroinflammation Through MIB1 Activation

  2021cites this paper
• Quercetin improves the impairment in memory function and attenuates hippocampal damage in cadmium chloride-intoxicated male rats by suppressing acetylcholinesterase and concomitant activation of SIRT1 signaling

  2021cites this paper
• Extracellular Vesicles as Drug Delivery System for Treatment of Neurodegenerative Disorders: Optimization of the Cell Source.

  2021cites this paper
• Naive BM-derived stem cells (Neuro-Cells) may modify acute and chronic neurodegenerative disorders by modulating macrophage behaviors

  2021cites this paper
• Gut dysbiosis, defective autophagy and altered immune responses in neurodegenerative diseases: Tales of a vicious cycle.

  2021cites this paper
• Revisiting Apathy in Alzheimer's Disease: From Conceptualization to Therapeutic Approaches

  2021cites this paper
• Neurogenic and anti-inflammatory effects of probiotics in Parkinson's disease: a systematic review of preclinical and clinical evidence.

  2021cites this paper
• Towards PET imaging of the dynamic phenotypes of microglia

  2021cites this paper
• [Macrophage migration inhibitory factor meditates MPP+/MPTP-induced NLRP3 inflammasome activation in microglia cells].

  2021cites this paper
• (-)-Syringaresinol suppressed LPS-induced microglia activation via downregulation of NF-κB p65 signaling and interaction with ERβ.

  2021cites this paper
• Molecular Communication Between Neuronal Networks and Intestinal Epithelial Cells in Gut Inflammation and Parkinson's Disease

  2021cites this paper
• Association between inflammatory bowel diseases and Parkinson's disease: systematic review and meta-analysis

  2021influential citation
• The Role of Chronic Inflammation in Various Diseases and Anti‐inflammatory Therapies Containing Natural Products

  2021cites this paper
• Possible Link between SARS-CoV-2 Infection and Parkinson’s Disease: The Role of Toll-Like Receptor 4

  2021cites this paper
• FGF, Mechanism of Action, Role in Parkinson’s Disease, and Therapeutics

  2021cites this paper
• Neuropharmacological Effects of Quercetin: A Literature-Based Review

  2021cites this paper
• A LRRK2 GTP Binding Inhibitor, 68, Reduces LPS-Induced Signaling Events and TNF-α Release in Human Lymphoblasts

  2021cites this paper
• Apoptosis in health and diseases of the eye and brain.

  2021cites this paper
• Potential role of cannabidiol in Parkinson’s disease by targeting the WNT/β-catenin pathway, oxidative stress and inflammation

  2021cites this paper
• Microglia Activation in Basal Ganglia Is a Late Event in Huntington Disease Pathophysiology

  2021cites this paper
• The involvement of NLRP3 inflammasome in the treatment of neurodegenerative diseases.

  2021cites this paper
• Selegiline reduces daytime sleepiness in patients with Parkinson's disease

  2021cites this paper
• Risk factors of Parkinson's disease: Simultaneous assessment, interactions and etiological subtypes.

  2020cites this paper
• Label-free quantum dot conjugates for human protein IL-2 based on molecularly imprinted polymers

  2020cites this paper
• INCREASED PLASMA PHOSPHATIDYLCHOLINE/LYSOPHOSPHATIDYLCHOLINE RATIOS IN PATIENTS WITH PARKINSON'S DISEASE.

  2020cites this paper
• Targeting the Microglial NLRP3 Inflammasome and Its Role in Parkinson's Disease

  2020cites this paper
• Post mortem evaluation of inflammation, oxidative stress, and PPARγ activation in a nonhuman primate model of cardiac sympathetic neurodegeneration

  2020cites this paper
• Effect of metformin and indole-3-carbinol on a rat model of Parkinson’s disease induced by 6-hydroxydopamine

  2020cites this paper
• Circadian rhythms, Neuroinflammation and Oxidative Stress in the Story of Parkinson’s Disease

  2020influential citation
• Proinflammatory cytokines in Parkinson’s disease and current treatment approaches

  2020cites this paper
• miR‐29c‐3p inhibits microglial NLRP3 inflammasome activation by targeting NFAT5 in Parkinson's disease

  2020cites this paper
• Nurr1Cd11bcre conditional knockout mice display inflammatory injury to nigrostriatal dopaminergic neurons.

  2020cites this paper
• The role of prebiotics in cognition, anxiety, and depression.

  2020cites this paper
• Higher risk of Parkinson disease in patients with primary Sjögren’s syndrome

  2020cites this paper
• The NLRP3 Inflammasome as a Critical Actor in the Inflammaging Process

  2020cites this paper
• Subthalamic nucleus deep brain stimulation suppresses neuroinflammation by Fractalkine pathway in Parkinson's disease rat model.

  2020cites this paper